Clinical Trial Update: A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355 [Phase 1]

View source ↗

Summary

A Phase 1 study completed to assess the relative bioavailability of PF-00258210 administered alone or with PF-00610355 in asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PF-00258210
• PF-00610355

Snippet

Sponsor: Pfizer | Conditions: Asthma | Phase 1 | Status: COMPLETED